Evaluating the effect of anti-inflammatory diet and flax seed on disease activity in rheumatoid arthritis patients

Evaluating the effect of anti-inflammatory diet and flax seed on disease activity, inflammatory factors and quality of life in rheumatoid arthritis patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190923044858N1

Enrollment

120

Registered

2020-02-06

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis.

Interventions

Intervention 1: Intervention group1: Anti-inflammatory diet and flaxseed powder (30 g daily in two 15-g serving) for 3 months of diet and consumption of flaxseed. Intervention 2: Intervention group

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Disease duration of at least 6 months, active disease with DAS28 criterion greater than 2.6, clinically established and controlled by the drugs and age range 18 to 70 years.

Exclusion criteria

Exclusion criteria: Individuals will not be included in the study if they have infectious diseases, cancer, and other inflammatory diseases such as liver and kidney failure, adherence to specific diets, drug dependence, alcohol consumption, and repeated use of herbal remedies.

Design outcomes

Primary

Measure	Time frame
Interlukin6. Timepoint: The beginning and the end of the study. Method of measurement: laboratory kit.;Anti-CCP. Timepoint: The beginning and the end of the study. Method of measurement: laboratory kit.;DAS28. Timepoint: The beginning and the end of the study. Method of measurement: Through examination.;Early Morning Stiffness. Timepoint: The beginning and the end of the study. Method of measurement: questionnaire.;Visual Analogue Scale. Timepoint: The beginning and the end of the study. Method of measurement: questionnaire.;Erythrocyte Sedimentation Rate. Timepoint: The beginning and the end of the study. Method of measurement: laboratory kit.	—

Measure

Time frame

Interlukin6. Timepoint: The beginning and the end of the study. Method of measurement: laboratory kit.;Anti-CCP. Timepoint: The beginning and the end of the study. Method of measurement: laboratory kit.;DAS28. Timepoint: The beginning and the end of the study. Method of measurement: Through examination.;Early Morning Stiffness. Timepoint: The beginning and the end of the study. Method of measurement: questionnaire.;Visual Analogue Scale. Timepoint: The beginning and the end of the study. Method of measurement: questionnaire.;Erythrocyte Sedimentation Rate. Timepoint: The beginning and the end of the study. Method of measurement: laboratory kit.

—

Secondary

Measure	Time frame
Weight. Timepoint: The beginning and the end of the study. Method of measurement: Digital scales.;Waist. Timepoint: The beginning and the end of the study. Method of measurement: Tape measure.;Health Status. Timepoint: The beginning and the end of the study. Method of measurement: Health Status Questionnaire (SF-36).;Health assessment. Timepoint: The beginning and the end of the study. Method of measurement: Stanford health assessment questionnaire(HAQ 8-item).;3 days food record. Timepoint: The beginning, middle and end of the study. Method of measurement: food record.	—

Measure

Time frame

Weight. Timepoint: The beginning and the end of the study. Method of measurement: Digital scales.;Waist. Timepoint: The beginning and the end of the study. Method of measurement: Tape measure.;Health Status. Timepoint: The beginning and the end of the study. Method of measurement: Health Status Questionnaire (SF-36).;Health assessment. Timepoint: The beginning and the end of the study. Method of measurement: Stanford health assessment questionnaire(HAQ 8-item).;3 days food record. Timepoint: The beginning, middle and end of the study. Method of measurement: food record.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Akhlaghi?

Shiraz University of Medical Sciences

msm.akhlaghi@gmail.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 20, 2026